Handbook of clinical drug data.pdf - Me and My Life

908 DRUG USE IN SPECIAL POPULATIONS191. Qvist N et al. Cimetidine as pre-anesthetic agent for cesarean section: perinatal effects on the infant, the placentaltransfer of cimetidine and its elimination in the infants. J Perinat Med 1985;13:179–83.192. Ikenoue T et al. Effects of ranitidine on maternal gastric juice and neonates when administered prior to caesareansection. Aliment Pharmacol Ther 1991;5:315–8.193. Seto A et al. Pregnancy outcome following first trimester exposure to antihistamines: a meta-analysis. Am JPerinatol 1997;14:119–24.194. Slone D et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortalityrate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128:486–8.195. Aselton P et al. First-trimester drug use and congenital disorders. Obstet Gynecol 1985;65:451–5.196. McKeigue PM et al. Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies. Teratology1994;50:27–37.197. Mogadam M et al. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids onfetal outcome. Gastroenterology 1981;80:72–6.198. Moody GA. The effects of chronic ill health and treatment with sulphasalazine on fertility amongst men andwomen with inflammatory bowel disease in Leicestershire. Int J Colorectal Dis 1997;12:220–4.199. Diav-Citrin O et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study.Gastroenterology 1998;114:23–8.200. Marteau P et al. Foetal outcome in women with inflammatory bowel disease treated during pregnancy withoral mesalazine microgranules. Aliment Pharmacol Ther 1998;12:1101–8.201. Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy andfetal outcome. J Clin Gastroenterol 1984;6:211–6.202. Meyers S, Sacher DB. Medical management of Crohn’s disease. Hepatogastroenterology 1990;37:42–55.203. Hall JG et al. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122–40.204. Ginsberg JS et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197–203.205. Ginsberg JS, Hirsh J. Use of anticoagulants during pregnancy. Chest 1989;95(suppl):156S–60.206. Nageotte MP et al. Anticoagulation in pregnancy. Am J Obstet Gynecol 1981;141:472–3.207. Nelson-Piercy C et al. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixtyninepregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176:1062–8.208. Schneider DM et al. Retrospective evaluation of the safety and efficacy of low-molecular-weight heparin asthromboprophylaxis during pregnancy. Am J Obstet Gynecol 1997;177:1567–8. Letter.209. Iturbe-Alessio I et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl JMed 1986;315:1390–3.210. Born D et al. Pregnancy in patients with prosthetic heart valves: the effects of anticoagulation on mother,fetus, and neonate. Am Heart J 1992;124:413–7.211. Gärtner BC et al. Phenprocoumon therapy during pregnancy: case report and comparison of the teratogenicrisk of different coumarin derivatives. Z Geburtshilfe Perinatol 1993;197:262–5.212. Pati S, Helmbrecht GD. Congenital schizencephaly associated with in utero warfarin exposure. Reprod Toxicol1994;8:115–20.213. Normann EK, Stray-Pedersen B. Warfarin-induced fetal diaphragmatic hernia: case report. Br J Obstet Gynaecol1989;96:729–30.214. Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology 1995;51:45–6.215. Fitzsimons R et al. Outcome of pregnancy in women requiring corticosteroids for severe asthma. J AllergyClin Immunol 1986;78:349–53.216. Avery ME et al. Update on prenatal steroid for prevention of respiratory distress. Am J Obstet Gynecol1986;155:2–5.217. Van Marter LJ et al. Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics1990;86:331–6.218. Smolder-de Haas H et al. Physical development and medical history of children who were treated antenatallywith corticosteroids to prevent respiratory distress syndrome: a 10- to 12-year follow-up. Pediatrics 1990;85:65–70.219. Saenger P. Abnormal sex differentiation. J Pediatr 1984;104:1–17.220. Brunskill PJ. The effect of fetal exposure to danazol. Br J Obstet Gynaecol 1992;99:212–5.221. Rosenn B et al. Minor congenital malformations in infants of insulin-dependent diabetic women: associationwith poor glycemic control. Obstet Gynecol 1990;70:745–9.222. Piacquadio K et al. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet 1991;338:866–9.223. Hellmuth E et al. Congenital malformations in offspring of diabetic women treated with oral hypoglycaemicagents during embryogenesis. Diabetic Med 1994;11:471–4.224. Saili A, Sarna MS. Tolbutamide: teratogenic effects. Indian Pediatr 1991;28:936–40.